Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beremagene geperpavec - Krystal Biotech

Next Previous
Drug Profile

Beremagene geperpavec - Krystal Biotech

Alternative Names: B-VEC; Bercolagene telserpavec; Beremagene geperpavec-svdt; HSV1-COL7; KB-103; KB-803; VYJUVEK

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Krystal Biotech
  • Class Gene therapies; Skin disorder therapies
  • Mechanism of Action COL7A1 protein replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa dystrophica
  • New Molecular Entity No

Highest Development Phases

  • Marketed Epidermolysis bullosa dystrophica

Most Recent Events

  • 15 Sep 2025 FDA approved a label update for VYJUVEK® (beremagene geperpavec-svdt), expanding its use to include dystrophic epidermolysis bullosa patients from birth and allowing greater flexibility in application and wound care
  • 04 Aug 2025 Krystal Biotech intends to launch beremagene geperpavec for Epidermolysis bullosa dystrophica in France (Topical) in the fourth quarter of 2025
  • 25 Jul 2025 Registered for Epidermolysis bullosa dystrophica (In adolescents, In children, In the elderly, In infants, In adults) in Japan (Topical)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top